Fig. 4
From: Nucleoside-Lipid-Based Nanocarriers for Sorafenib Delivery
Cytotoxicity effect of sorafenib or SLNs. a) Comparison of the cytotoxicity with free Sorafenib or SLNs of Sorafenib in 4 cells lines (2 luminal B breast cancer and 2 hepatocarcinomas) after quantification with MTS assay on 3 wells at 5 μM of free Sorafenib, 2.8 μM of NPs Sorafenib/DOTAU (SLN+) and 4 μM of NPs Sorafenib/diC16dT (SLN-). b) Cell viability assay (MDA-MB-134 cells) in the presence of free sorafenib (limited of solubility ), SLN+ (grey) or SLN- (black)